Literature DB >> 9725366

Lung transplantation for cystic fibrosis: effective and durable therapy in a high-risk group.

T M Egan1, F C Detterbeck, M R Mill, K K Gott, J B Rea, J McSweeney, R M Aris, L J Paradowski.   

Abstract

BACKGROUND: The purpose of this study was to review our experience with lung transplantation in patients with end-stage cystic fibrosis.
METHODS: Eight-two patients with cystic fibrosis have undergone bilateral lung transplantation (n=76) or bilateral lower lobe transplantation (n=6) since October 1990.
RESULTS: Actuarial survival for the entire cohort is 79% at 1 year and 57% at 5 years. The development of bronchiolitis obliterans syndrome is the leading cause of death after the first year. Freedom from bronchiolitis obliterans syndrome is 84% at 1 year and 51% at 3 years. Pulmonary function tests improve dramatically in recipients. There was no association between death within 1 year and recipient age, weight, graft ischemic time, cytomegalovirus seronegativity, or the presence of pan-resistant organisms. Similarly, there was no association between the development of bronchiolitis obliterans syndrome within 2 years and ischemic time, number of rejection episodes, cytomegalovirus seronegativity, or the presence of panresistant organisms.
CONCLUSIONS: Despite their poor nutritional status and the presence of multiply resistant organisms, patients with cystic fibrosis can undergo bilateral lung transplantation with acceptable morbidity and mortality.

Entities:  

Mesh:

Year:  1998        PMID: 9725366     DOI: 10.1016/s0003-4975(98)00496-2

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  3 in total

1.  Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation.

Authors:  W Chalermskulrat; N Sood; I P Neuringer; T M Hecker; L Chang; M P Rivera; L J Paradowski; R M Aris
Journal:  Thorax       Date:  2006-04-06       Impact factor: 9.139

2.  Religious and non-religious coping in lung transplant candidates: does adding god to the picture tell us more?

Authors:  Eileen J Burker; Donna M Evon; Jan A Sedway; Thomas Egan
Journal:  J Behav Med       Date:  2005-10-20

Review 3.  Inflammation in lung transplantation for CF. Immunosuppression and modulation of inflammation.

Authors:  George B Mallory
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.